Jerusalem, Israel – Oct 21, 2018

NovellusDx was selected to present its Deep Learning machine learning framework to predict the activity and drug response of unknown mutations. The framework developed on Nvidia’s DGX workstations harnesses the tremendous power of Graphical Processing Units (GPU) computing to accelerate the training of the deep network.

NovellusDx was also selected to be highlighted in the keynote presentation of Bill Dally, Nvidia’s chief scientist, as a breakthrough healthcare technology harnessing the power of GPU’s.

See more at :

To view the keynote presentation:

Michael Vidne, CCO, presents "Using Deep Learning to Predict Activity and Drug Response of Unknown Mutations" at NVIDIA's GTC conference




NovellusDx’s mission is to provide functional information about mutations and their responses to drugs so that oncologists can treat patients with precision therapies and bio-pharmaceutical companies can develop drugs more effectively. The NovellusDx approach is to monitor the functional effects of mutations and observe the effects of drugs, drug combinations and drug candidates on the activity level caused by the mutations. NovellusDx’s headquarters and research and development operations are based in Jerusalem, Israel.

To learn more about NovellusDx please visit